Literature DB >> 10678181

Nf1 and Gmcsf interact in myeloid leukemogenesis.

R A Birnbaum1, A O'Marcaigh, Z Wardak, Y Y Zhang, G Dranoff, T Jacks, D W Clapp, K M Shannon.   

Abstract

The NF1 tumor suppressor gene encodes neurofibromin, a GTPase-activating protein (GAP) for p21ras (Ras). Children with NF1 are predisposed to juvenile myelomonocytic leukemia (JMML). Some heterozygous Nf1 mutant mice develop a similar myeloproliferative disorder (MPD), and adoptive transfer of Nf1-deficient fetal liver cells consistently induces this MPD. Human JMML and murine Nf1-deficient cells are hypersensitive to granulocyte-macrophage colony-stimulating factor (GM-CSF) in methylcellulose cultures. We generated hematopoietic cells deficient in both Nf1 and Gmcsf to test whether GM-CSF is required to drive excessive proliferation of Nf1-/- cells in vivo. Here we show that GM-CSF play a central role in establishing and maintaining the MPD and that recipients engrafted with Nf1-/- Gmcsf-/- hematopoietic cells are hypersensitive to exogenous GM-CSF.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10678181     DOI: 10.1016/s1097-2765(00)80415-3

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  51 in total

Review 1.  Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras.

Authors:  Anica Wandler; Kevin Shannon
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

2.  IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease.

Authors:  Stephane Wong; Jami McLaughlin; Donghui Cheng; Kevin Shannon; Lorraine Robb; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

3.  Molecular basis and clonal evolution of myeloproliferative neoplasms.

Authors:  Roland Jäger; Robert Kralovics
Journal:  Haematologica       Date:  2010-04       Impact factor: 9.941

Review 4.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

5.  Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1.

Authors:  Jae-Lyun Lee; Jin Young Kim; Min-Hee Ryu; Hye Jin Kang; Heung Moon Chang; Tae-Won Kim; Hyoungnam Lee; Ji Hyun Park; Hee Cheol Kim; Jung Sun Kim; Yoon-Koo Kang
Journal:  Dig Dis Sci       Date:  2006-06       Impact factor: 3.199

6.  Regulation of myeloproliferation and M2 macrophage programming in mice by Lyn/Hck, SHIP, and Stat5.

Authors:  Wenbin Xiao; Hong Hong; Yuko Kawakami; Clifford A Lowell; Toshiaki Kawakami
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

7.  Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.

Authors:  Gordon Chan; Demetrios Kalaitzidis; Tatiana Usenko; Jeffery L Kutok; Wentian Yang; M Golam Mohi; Benjamin G Neel
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

8.  High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

Authors:  Jeffrey W Tyner; Heidi Erickson; Michael W N Deininger; Stephanie G Willis; Christopher A Eide; Ross L Levine; Michael C Heinrich; Norbert Gattermann; D Gary Gilliland; Brian J Druker; Marc M Loriaux
Journal:  Blood       Date:  2008-12-15       Impact factor: 22.113

9.  Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk.

Authors:  Karl Staser; Su-Jung Park; Steven D Rhodes; Yi Zeng; Yong Zheng He; Matthew A Shew; Jeffrey R Gehlhausen; Donna Cerabona; Keshav Menon; Shi Chen; Zejin Sun; Jin Yuan; David A Ingram; Grzegorz Nalepa; Feng-Chun Yang; D Wade Clapp
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

10.  Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2.

Authors:  Xiaoqin Wu; Gang Xu; Xiaobo Li; Weiren Xu; Qianjin Li; Wei Liu; Karen A Kirby; Mignon L Loh; Jun Li; Stefan G Sarafianos; Cheng-Kui Qu
Journal:  J Med Chem       Date:  2018-12-05       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.